Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 8, 2026

Methyl-binding DNA capture Sequencing for Patient Tissues
08:40

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

Array-based DNA methylation profiling for breast cancer subtype discrimination.

Ilse Van der Auwera1, Wayne Yu, Liping Suo

  • 1Translational Cancer Research Group, Laboratory of Pathology, University of Antwerp/University Hospital Antwerp, Oncology Center, Sint-Augustinus, Antwerp, Belgium.

Plos One
|September 11, 2010
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol.

BMC cancer·2026
Same author

Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical Outcome.

The Journal of investigative dermatology·2025
Same author

Multiscale Modeling Uncovers Macrophage Infiltration and TNF-α Signaling Networks for Targeting in Inflammatory Breast Cancer Tumor Emboli.

bioRxiv : the preprint server for biology·2025
Same author

IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.

Journal of hematology & oncology·2024
Same author

Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.

The Journal of urology·2023
Same author

Small Airway Disease in Pre-Chronic Obstructive Pulmonary Disease with Emphysema: A Cross-Sectional Study.

American journal of respiratory and critical care medicine·2023
Same journal

Epidemiological characteristics of amebiasis in Japan from 2001 to 2022.

PloS one·2026
Same journal

Longitudinal associations of academic stress with eating related patterns, nutrition, somatic indicators, and depressive symptoms in university students: A study protocol.

PloS one·2026
Same journal

Pollution removal efficiency enhancement by agricultural biomass additions in constructed wetlands: A framework integrating meta-analysis with explainable machine learning.

PloS one·2026
Same journal

Insulation failure mapping on power transformer bushing using FRA and electrostatic simulation.

PloS one·2026
Same journal

Enhancing medical Q&A systems with multimodal knowledge graphs and dual-layer attention mechanisms.

PloS one·2026
Same journal

UAMP: Consistent video object segmentation with uncertainty-aware memory propagation.

PloS one·2026
See all related articles

DNA methylation profiling can distinguish breast tumor subtypes and identify patients with poor prognosis. Aberrant DNA methylation is not the primary driver of inflammatory breast cancer (IBC).

Area of Science:

  • Oncology
  • Genomics
  • Epigenetics

Background:

  • Abnormal DNA methylation is a hallmark of breast cancer, often silencing tumor suppressor genes.
  • DNA methylation profiling offers a potential alternative to expression microarrays for breast tumor subtyping.

Purpose of the Study:

  • To investigate if methylomics can distinguish inflammatory breast cancer (IBC) from non-IBC phenotypes.
  • To correlate DNA methylation patterns with gene expression and clinical outcomes.

Main Methods:

  • Methylation profiling using Illumina Infinium Methylation Assay on 19 IBC and 43 non-IBC samples.
  • Correlation analysis between methylation values and gene expression profiles.
  • Identification of differentially methylated genes and CpG loci.

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Related Experiment Videos

Last Updated: Jun 8, 2026

Methyl-binding DNA capture Sequencing for Patient Tissues
08:40

Methyl-binding DNA capture Sequencing for Patient Tissues

Published on: October 31, 2016

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Main Results:

  • Methylation profiling separated tumors into high and low methylation groups, linked to DNMT3B mRNA levels.
  • The high methylation group showed enrichment for distant metastasis, poor prognosis, IBC, and high genomic grade index.
  • A set of 16 CpG loci accurately classified 97% of samples into methylation groups.
  • Only four differentially methylated genes were identified when comparing IBC and non-IBC.

Conclusions:

  • High DNA methylation levels in a subset of breast cancers correlate with increased DNMT3B expression and poor prognosis.
  • Aberrant DNA methylation is unlikely to be the primary molecular driver of IBC.
  • Methylomics provides a valuable tool for breast tumor classification and prognostic assessment.